NEW YORK (GenomeWeb News) – Metabolon said today that it has signed an intellectual property and development agreement with the University of Michigan related to its Prostarix line of prostate cancer diagnostics.
Under the terms of the agreement, Metabolon has taken an exclusive license for prostate cancer aggressiveness biomarkers that were discovered in a previous collaboration between the company and the university.
The company said that the IP it has licensed will provide it with a “significant advantage” in the field of prostate cancer diagnosis and will serve as the basis for its Prostarix test, which it expects to launch in late 2009.
The agreement also includes a sponsored research agreement with UM assistant professor of pathology Arun Sreekumar that will focus on studying the role of the biomarkers in cancer aggressiveness.
Financial terms of the agreement were not released.